Skip to main content

Table 2 Clinical and pathological outcome characteristics and diagnostic agreement

From: Application of ultrasound imaging biomarkers (HistoScanning™) improves staging reliability of prostate biopsies

 

Biopsy groups

P value

Image-guided

Systematic

Odds ratio (95% CI)

Pathological stagea, % (n)

  

0.86 (0.31–2.34)

.736

≤ pT2b

14.3 (11)

12.5 (11)

  

≥ pT2c

85.7 (66)

87.5 (77)

  

Clinical stagea, % (n)

  

10.35 (4.60–24.99)

< .001*

≤ cT2b

14.3 (11)

63.6 (56)

  

≥ cT2c

85.7 (66)

36.4 (32)

  

Stage agreement, % (n)

 Correct

89.6 (69)

46.6 (41)

  

 Over graded

5.2 (4)

1.1 (1)

  

 Under graded

5.2 (4)

52.3 (46)

  

 Cohen’s Kappa (95% CI)

0.58 (0.35 0.80)

0.11 (0.0 0.22)

  

 Pathological Gleasona, % (n)

  

10.35 (4.60–24.99)

.268

 ≤ 3 + 4

40.3 (31)

48.9 (43)

  

 ≥ 4 + 3

59.7 (46)

51.1 (45)

  

 Biopsy Gleasona, % (n)

  

3.36 (1.69–6.84)

< .001*

 ≤ 3 + 4

29.9 (23)

59.1 (52)

  

 ≥ 4 + 3

70.1 (54)

40.9 (36)

  

 Gleason score agreement, % (n)

    

 Correct

81.8 (63)

76.1 (67)

  

 Over graded

14.3 (11)

6.8 (6)

  

 Under graded

3.9 (3)

17 (15)

  

 Cohen’s Kappa (95% CI)

0.61 (0.39 0.82)

0.53 (0.32 0,73)

  
  1. CI confidence interval
  2. * Statistical significant difference (P < 0.05)
  3. aChi squared test/Fisher’s Exact test